About zanubrutinib
Bruton tyrosine kinase inhibitor
Used for
- Treats certain blood cancers, including chronic lymphocytic leukemia and mantle cell lymphoma.
- Also used for Waldenström macroglobulinemia and marginal zone lymphoma in eligible adults.
Usual adult dose
Usually 160 mg twice daily or 320 mg once daily by mouth; dosing may vary by condition or other medicines.
Common side effects
- Low blood cell counts, including neutropenia and anemia
- Bruising or bleeding
- Upper respiratory infections
- Diarrhea, rash, or muscle and joint pain
Important warnings
- Serious bleeding, infections, and low blood counts can occur.
- May cause irregular heartbeat, including atrial fibrillation, or high blood pressure.
- Rarely causes severe liver injury or second cancers, including skin cancer.
- May need to be paused around surgery; do not stop without the prescriber’s direction.
Pregnancy
May harm an unborn baby. Avoid pregnancy during treatment and for one week after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment and for two weeks after the last dose.
Interactions
- Strong or moderate CYP3A inhibitors can increase drug levels; dose changes may be needed.
- CYP3A inducers can lower drug levels and reduce effectiveness.
- Blood thinners and antiplatelet medicines may increase bleeding risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.